-
Je něco špatně v tomto záznamu ?
Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation
V. Kojecky, J. Matous, B. Kianicka, P. Dite, Z. Zadorova, J. Kubovy, M. Hlostova, M. Uher
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie
- MeSH
- aplikace orální MeSH
- cholekalciferol aplikace a dávkování MeSH
- dospělí MeSH
- idiopatické střevní záněty krev komplikace MeSH
- lidé středního věku MeSH
- lidé MeSH
- logistické modely MeSH
- multivariační analýza MeSH
- nedostatek vitaminu D komplikace farmakoterapie MeSH
- prospektivní studie MeSH
- rozvrh dávkování léků MeSH
- tělesná hmotnost MeSH
- vitamin D analogy a deriváty krev MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- Geografické názvy
- Česká republika MeSH
Objectives: Body weight is one of the factors affecting blood levels of 25-hydroxyvitamin D (25OHD). The aim of this study was to establish whether a vitamin D (vitD) weight-based dosing is more appropriate to a fixed daily dose in patients with inflammatory bowel disease (IBD).Materials/methods: This was an open label randomised trial. Patients with IBD were assigned to receive oral cholecalciferol at a dose of 28 IU/kg (IU/kg) or 2000 IU per day (IU/day) for 12 weeks during winter months. 25OHD plasma levels and other biochemical parameters were measured at baseline and after supplementation period. The primary outcome measure was 25OHD level after a follow-up period.Results: A total of 173 patients were analysed. The mean BMI was 25.5 ± 5.1 and initial mean 25OHD level was 62.7 ± 25.5 nmol/l. A similar increase (9.7 ± 26.9 vs 9.8 ± 26.7 nmol/l) in 25OHD levels occurred both in IU/kg and IU/day group. The proportion of subjects with normal and sub-normal levels following the substitution was comparable irrespective of body weight. The change in 25OHD level correlated positively only with the dose of vitD (p < .001) and negatively with the baseline 25OHD level (p < .001). A sustained 25OHD level of 75 nmol/l corresponds with a calculated daily vitD dose of 2034 IU.Conclusions: Weight-based dosing of vitamin D is not superior to a fixed dose in order to maintain stable 25OHD levels in IBD patients. Cholecalciferol dose of 2,000 IU/day is safe and sufficient during winter period.
2nd Department of Internal Medicine 3rd Faculty of Medicine Charles University Prague Czech Republic
Department of Gastroenterology Christchurch Hospital Christchurch New Zealand
Faculty of Medicine Masaryk University Brno Brno Czech Republic
Faculty of Medicine University of Ostrava Ostrava Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Institute of Health Information and Statistics of the Czech Republic Prague Czech Republic
Internal Department Bata Regional Hospital Zlin Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020531
- 003
- CZ-PrNML
- 005
- 20220117124007.0
- 007
- ta
- 008
- 210728s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/00365521.2020.1774921 $2 doi
- 035 __
- $a (PubMed)32538182
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kojecky, Vladimir $u Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic $u Internal Department, Bata Regional Hospital, Zlin, Czech Republic
- 245 10
- $a Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation / $c V. Kojecky, J. Matous, B. Kianicka, P. Dite, Z. Zadorova, J. Kubovy, M. Hlostova, M. Uher
- 520 9_
- $a Objectives: Body weight is one of the factors affecting blood levels of 25-hydroxyvitamin D (25OHD). The aim of this study was to establish whether a vitamin D (vitD) weight-based dosing is more appropriate to a fixed daily dose in patients with inflammatory bowel disease (IBD).Materials/methods: This was an open label randomised trial. Patients with IBD were assigned to receive oral cholecalciferol at a dose of 28 IU/kg (IU/kg) or 2000 IU per day (IU/day) for 12 weeks during winter months. 25OHD plasma levels and other biochemical parameters were measured at baseline and after supplementation period. The primary outcome measure was 25OHD level after a follow-up period.Results: A total of 173 patients were analysed. The mean BMI was 25.5 ± 5.1 and initial mean 25OHD level was 62.7 ± 25.5 nmol/l. A similar increase (9.7 ± 26.9 vs 9.8 ± 26.7 nmol/l) in 25OHD levels occurred both in IU/kg and IU/day group. The proportion of subjects with normal and sub-normal levels following the substitution was comparable irrespective of body weight. The change in 25OHD level correlated positively only with the dose of vitD (p < .001) and negatively with the baseline 25OHD level (p < .001). A sustained 25OHD level of 75 nmol/l corresponds with a calculated daily vitD dose of 2034 IU.Conclusions: Weight-based dosing of vitamin D is not superior to a fixed dose in order to maintain stable 25OHD levels in IBD patients. Cholecalciferol dose of 2,000 IU/day is safe and sufficient during winter period.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a tělesná hmotnost $7 D001835
- 650 _2
- $a cholekalciferol $x aplikace a dávkování $7 D002762
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a idiopatické střevní záněty $x krev $x komplikace $7 D015212
- 650 _2
- $a logistické modely $7 D016015
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multivariační analýza $7 D015999
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a vitamin D $x analogy a deriváty $x krev $7 D014807
- 650 _2
- $a nedostatek vitaminu D $x komplikace $x farmakoterapie $7 D014808
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Matous, Jan $u 2nd Department of Internal Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Kianicka, Bohuslav $u 2nd Department of Internal Medicine/Department of Gastroenterology, St. Anne´s University Hospital, Brno, Czech Republic
- 700 1_
- $a Dite, Petr $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Zadorova, Zdena $u 2nd Department of Internal Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Kubovy, Jan $u Department of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand
- 700 1_
- $a Hlostova, Martina $u Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic
- 700 1_
- $a Uher, Michal $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0237556
- 773 0_
- $w MED00010598 $t Scandinavian journal of gastroenterology $x 1502-7708 $g Roč. 55, č. 6 (2020), s. 671-676
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32538182 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20220117124007 $b ABA008
- 999 __
- $a ok $b bmc $g 1691160 $s 1140977
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 55 $c 6 $d 671-676 $e 20200613 $i 1502-7708 $m Scandinavian journal of gastroenterology $n Scand J Gastroenterol $x MED00010598
- LZP __
- $a Pubmed-20210728
